WHO Pre-qualifies Bharat Biotech's Rotavirus Vaccine

The rotavirus vaccine ROTAVAC which was launched in 2015 to fight diarrhea has been approved for WHO-prequalification making the vaccine accessible.

The World Health Organisation (WHO) has awarded pre-qualification to Bharat Biotech's rotavirus vaccine ROTAVAC.

The vaccine prevent infant deaths and hospitalization due to rotavirus diarrhea was launched by Prime Minister Narendra Modi in 2015 and is one of the first novel vaccines to be developed completely by a developing country, the Hyderabad-based vaccine manufacturer said.

'Made in India' Rotavirus Vaccine Claims to be Cheapest
India's first indigenously developed and manufactured rotavirus vaccine 'Rotavac' will be available for sale at the rate of around Rs 60 per dose from next week.

‘WHO-prequalification can accelerate the availability of the ROTAVAC to the developing countries with the highest burden of rotavirus infection.’

WHO pre-qualification is necessary for UN agencies and Gavi, the Vaccine Alliance, to purchase the vaccine in partnership with developing countries and will help accelerate the availability of the ROTAVAC to the developing countries with the highest burden of the disease.

India introduced ROTAVAC into its national immunization programme in 2016, with about 35 million doses delivered so far.

"The true impact of vaccines can be seen when vaccinations are carried out in affected populations. The government of India has given a big boost by making ROTAVAC available to millions in India already," said Krishna Ella, Chairman and Managing Director of Bharat Biotech.

Should Risk of Intussusception With Rotavirus Vaccine Deter the Use of the Vaccine?
A Rotavirus vaccine was introduced in the past however it had to be withdrawn since 1 out of 10000 infants administered the vaccine suffered a serious complication called intussusception.

"Bharat Biotech's track record of life-saving vaccines is a testimony to the company's longstanding commitment to making affordable vaccines for the developing world. ROTAVAC has been supplied to low-income countries at $1 per dose, with the feasibility for further 30 percent price reductions, based on the procurement of around 100 million doses for these countries," Ella added.

$35 billion needed globally for immunization
Globally $35 billion will be required for immunization in the next ten years to save an additional ten million lives.

Source-IANS

Keeping Rotavirus at Bay
Virus such as influenza via specific characteristics of viral ribonucleic acid can be detected by our immunosensory system.